BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 17464989)

  • 1. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
    Wong CM; Ng YL; Lee JM; Wong CC; Cheung OF; Chan CY; Tung EK; Ching YP; Ng IO
    Hepatology; 2007 May; 45(5):1129-38. PubMed ID: 17464989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
    Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
    J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
    Neumann O; Kesselmeier M; Geffers R; Pellegrino R; Radlwimmer B; Hoffmann K; Ehemann V; Schemmer P; Schirmacher P; Lorenzo Bermejo J; Longerich T
    Hepatology; 2012 Nov; 56(5):1817-27. PubMed ID: 22689435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications.
    Zhang C; Li H; Wang Y; Liu W; Zhang Q; Zhang T; Zhang X; Han B; Zhou G
    J Hepatol; 2010 Nov; 53(5):889-95. PubMed ID: 20675009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.
    Zhou X; Popescu NC; Klein G; Imreh S
    Cancer Genet Cytogenet; 2007 Aug; 177(1):6-15. PubMed ID: 17693185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
    Chan DW; Lee JM; Chan PC; Ng IO
    Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma.
    Fukai K; Yokosuka O; Chiba T; Hirasawa Y; Tada M; Imazeki F; Kataoka H; Saisho H
    Cancer Res; 2003 Dec; 63(24):8674-9. PubMed ID: 14695180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
    Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
    Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking.
    Nishida N; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Inoue T; Minami Y; Ueshima K; Sakurai T; Kudo M
    Dig Dis; 2014; 32(6):740-6. PubMed ID: 25376292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer.
    Takada H; Wakabayashi N; Dohi O; Yasui K; Sakakura C; Mitsufuji S; Taniwaki M; Yoshikawa T
    Cancer Genet Cytogenet; 2010 Feb; 197(1):16-24. PubMed ID: 20113832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of the alcohol dehydrogenase 1B (ADH1B) and ADH1C genes by DNA methylation and histone deacetylation.
    Dannenberg LO; Chen HJ; Tian H; Edenberg HJ
    Alcohol Clin Exp Res; 2006 Jun; 30(6):928-37. PubMed ID: 16737450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.
    Acun T; Demir K; Oztas E; Arango D; Yakicier MC
    OMICS; 2015 Apr; 19(4):220-9. PubMed ID: 25831062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
    Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.
    Foltz G; Ryu GY; Yoon JG; Nelson T; Fahey J; Frakes A; Lee H; Field L; Zander K; Sibenaller Z; Ryken TC; Vibhakar R; Hood L; Madan A
    Cancer Res; 2006 Jul; 66(13):6665-74. PubMed ID: 16818640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions.
    Tung EK; Wong CM; Yau TO; Lee JM; Ching YP; Ng IO
    Int J Cancer; 2009 Apr; 124(8):1811-9. PubMed ID: 19107935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
    J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.
    Quan H; Zhou F; Nie D; Chen Q; Cai X; Shan X; Zhou Z; Chen K; Huang A; Li S; Tang N
    Oncogene; 2014 May; 33(22):2826-35. PubMed ID: 23770846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma.
    Hayashi M; Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Yamada S; Fujii T; Sugimoto H; Takeda S; Kodera Y
    J Surg Oncol; 2012 Mar; 105(4):381-6. PubMed ID: 22052684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
    Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
    Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
    Yan Q; Zhang ZF; Chen XP; Gutmann DH; Xiong M; Xiao ZY; Huang ZY
    Int J Oncol; 2008 May; 32(5):1057-63. PubMed ID: 18425332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.